Review of pregnancy labeling of prescription drugs: Is the current system adequate to inform of risks?

被引:68
作者
Doering, PL
Boothby, LA
Cheok, M
机构
[1] Univ Florida, Coll Pharm, Dept Pharm Practice, Gainesville, FL 32611 USA
[2] Columbus Reg Drug Informat Ctr, Columbus, GA USA
[3] Univ Bonn, D-5300 Bonn, Germany
[4] St Judes Med Ctr, Fullerton, CA USA
关键词
pregnancy; drug therapy; labeling; evidence-based medicine;
D O I
10.1067/mob.2002.125740
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Evidence-based medicine that is designed to guide benefit/risk drug therapy decisions does not exist for pregnant women. The types of studies that do exist are usually conducted in animals, which may not reflect human benefits and risks. The types of studies that do exist in humans are typically limited and, at best, may show an "association" between a particular drug therapy and an undesirable effect. This review outlines the difficulties that are associated with the assessment of the benefits/risks of drug therapy during pregnancy, the history of the Food and Drug Administration regulations for labeling prescription drugs, and the strengths and weaknesses of the current Food and Drug Administration pregnancy labeling system. Proposed changes to the current system are reviewed.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 30 条
  • [1] Risk classification systems for drug use during pregnancy - Are they a reliable source of information?
    Addis, A
    Sharabi, S
    Bonati, M
    [J]. DRUG SAFETY, 2000, 23 (03) : 245 - 253
  • [2] AGNER SI, 1989, ASHP MID CLIN M, V24, P170
  • [3] [Anonymous], 2001, OBSTET GYNECOL, V98, P177
  • [4] [Anonymous], 1979, FDA Drug Bull, V9, P23
  • [5] Formed by thalidomide: Mass torts as a false cure for toxic exposure
    Bernstein, A
    [J]. COLUMBIA LAW REVIEW, 1997, 97 (07) : 2153 - 2176
  • [6] CODERO JF, 1983, CLIN OBSTET GYNECOL, V26, P418
  • [7] VAGINAL SPERMICIDES, CHROMOSOMAL-ABNORMALITIES AND LIMB REDUCTION DEFECTS
    CORDERO, JF
    LAYDE, PM
    [J]. FAMILY PLANNING PERSPECTIVES, 1983, 15 (01): : 16 - 18
  • [8] Thalidomide: was the tragedy preventable?
    Dally, A
    [J]. LANCET, 1998, 351 (9110) : 1197 - 1199
  • [9] *DEP HHS, 1997, PREGNANCY LABELING C, V62, P41061
  • [10] Doering PL, 1992, NATL ASS RETAIL DRUG, P53